-
Apr 28, 2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 28, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer...
-
Apr 14, 2008Study demonstrates anti-tumor activity in advanced basal cell carcinoma patients
CAMBRIDGE, Mass., Apr 14, 2008 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment,...
-
Apr 14, 2008Multi-targeted small molecule drug candidate demonstrates potential in preclinical testing as a therapeutic for liver cancer
CAMBRIDGE, Mass., Apr 14, 2008 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today...
-
Apr 8, 2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 9, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today...
-
Mar 14, 2008Genentech indicates that it expects to initiate three Phase II clinical trials of GDC-0449 in 2008
CAMBRIDGE, Mass., Mar 14, 2008 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today...
-
Mar 10, 2008Company to Seek New Partner for Development Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 10, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today...
-
Mar 7, 2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 7, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today...
-
Feb 14, 2008
CAMBRIDGE, Mass., Feb 14, 2008 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ:CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today...
-
Feb 5, 2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today...
-
Dec 28, 2007
CAMBRIDGE, Mass., Dec 28, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
-
Dec 19, 2007
CAMBRIDGE, Mass., Dec 19, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
-
Dec 12, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 12, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
-
Nov 2, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 2, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment,...
-
Oct 25, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
-
Oct 23, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 23, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, will...
-
Oct 17, 2007Curis Presents Preclinical Data on CUDC-101
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 17, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
-
Oct 16, 2007Curis to receive $3 million payment
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 16, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
-
Oct 1, 2007
CAMBRIDGE, Mass., Oct 31, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
-
Sep 30, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today...
-
Sep 3, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 3, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today...
-
Aug 28, 2007
CAMBRIDGE, Mass., Aug 28, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment,...
-
Aug 24, 2007HDAC Inhibitory Activity Disclosed as a Core Component of Multi-Target New Chemical Entity Platform
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
-
Jul 31, 2007
CAMBRIDGE, Mass., Jul 31, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today...
-
Jul 24, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 24, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, will release...